These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 37435073)

  • 21. Immune responses in healthy adults elicited by a bivalent norovirus vaccine candidate composed of GI.4 and GII.4 VLPs without adjuvant.
    Waerlop G; Janssens Y; Jacobs B; Jarczowski F; Diessner A; Leroux-Roels G; Klimyuk V; Leroux-Roels I; Thieme F
    Front Immunol; 2023; 14():1188431. PubMed ID: 37435073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Robust mucosal-homing antibody-secreting B cell responses induced by intramuscular administration of adjuvanted bivalent human norovirus-like particle vaccine.
    Sundararajan A; Sangster MY; Frey S; Atmar RL; Chen WH; Ferreira J; Bargatze R; Mendelman PM; Treanor JJ; Topham DJ
    Vaccine; 2015 Jan; 33(4):568-76. PubMed ID: 25444793
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations.
    Parra GI; Bok K; Taylor R; Haynes JR; Sosnovtsev SV; Richardson C; Green KY
    Vaccine; 2012 May; 30(24):3580-6. PubMed ID: 22469864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serological Correlates of Protection against a GII.4 Norovirus.
    Atmar RL; Bernstein DI; Lyon GM; Treanor JJ; Al-Ibrahim MS; Graham DY; Vinjé J; Jiang X; Gregoricus N; Frenck RW; Moe CL; Chen WH; Ferreira J; Barrett J; Opekun AR; Estes MK; Borkowski A; Baehner F; Goodwin R; Edmonds A; Mendelman PM
    Clin Vaccine Immunol; 2015 Aug; 22(8):923-9. PubMed ID: 26041041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Harmonization and qualification of intracellular cytokine staining to measure influenza-specific CD4
    Begue S; Waerlop G; Salaun B; Janssens M; Bellamy D; Cox RJ; Davies R; Gianchecchi E; Medaglini D; Montomoli E; Pettini E; Leroux-Roels G; Clement F; Pagnon A
    Front Immunol; 2022; 13():982887. PubMed ID: 36341380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine.
    Leroux-Roels I; Maes C; Joye J; Jacobs B; Jarczowski F; Diessner A; Janssens Y; Waerlop G; Tamminen K; Heinimäki S; Blazevic V; Leroux-Roels G; Klimyuk V; Adachi H; Hiruta K; Thieme F
    Front Immunol; 2022; 13():1021500. PubMed ID: 36275772
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Harmonization and qualification of an IFN-γ Enzyme-Linked ImmunoSpot assay (ELISPOT) to measure influenza-specific cell-mediated immunity within the FLUCOP consortium.
    Waerlop G; Leroux-Roels G; Lambe T; Bellamy D; Medaglini D; Pettini E; Cox RJ; Trieu MC; Davies R; Bredholt G; Montomoli E; Gianchecchi E; Clement F
    Front Immunol; 2022; 13():984642. PubMed ID: 36159843
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of cell-mediated immunity against influenza and its implications for vaccine evaluation.
    Janssens Y; Joye J; Waerlop G; Clement F; Leroux-Roels G; Leroux-Roels I
    Front Immunol; 2022; 13():959379. PubMed ID: 36052083
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CRISPR-Cas9-Based Technology for Studying Enteric Virus Infection.
    Hirano J; Murakami K; Hayashi T
    Front Genome Ed; 2022; 4():888878. PubMed ID: 35755450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity of a bivalent virus-like particle norovirus vaccine in children from 1 to 8 years of age: A phase 2 randomized, double-blind study.
    Vesikari T; Saez-Llorens X; Blazevic V; Lopez P; Lopez E; Masuda T; Mendelman PM; Liu M; Sherwood J; Baehner F; Borkowski A
    Vaccine; 2022 Jun; 40(26):3588-3596. PubMed ID: 35595661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outbreaks of Gastroenteritis Due to Norovirus in Schools and Summer Camps in Catalonia, 2017-2019.
    Parrón I; Barrabeig I; Soldevila N; Bartolomé R; Guix S; Rius C; Cornejo-Sánchez T; Izquierdo C; Domínguez À;
    Microbiol Spectr; 2022 Jun; 10(3):e0011922. PubMed ID: 35543555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Global and regional circulation trends of norovirus genotypes and recombinants, 1995-2019: A comprehensive review of sequences from public databases.
    Kendra JA; Tohma K; Parra GI
    Rev Med Virol; 2022 Sep; 32(5):e2354. PubMed ID: 35481689
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized, Double-Blind, Reference-Controlled, Phase 2a Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine.
    Leroux-Roels I; Waerlop G; Tourneur J; De Boever F; Maes C; Bruhwyler J; Guyon-Gellin D; Moris P; Del Campo J; Willems P; Leroux-Roels G; Le Vert A; Nicolas F
    Front Immunol; 2022; 13():852904. PubMed ID: 35464450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Generation of CRISPR-Cas9-mediated genetic knockout human intestinal tissue-derived enteroid lines by lentivirus transduction and single-cell cloning.
    Lin SC; Haga K; Zeng XL; Estes MK
    Nat Protoc; 2022 Apr; 17(4):1004-1027. PubMed ID: 35197604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Norovirus Vaccines: Current Clinical Development and Challenges.
    Tan M
    Pathogens; 2021 Dec; 10(12):. PubMed ID: 34959596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Norovirus-glycan interactions - how strong are they really?
    Peters T; Creutznacher R; Maass T; Mallagaray A; Ogrissek P; Taube S; Thiede L; Uetrecht C
    Biochem Soc Trans; 2022 Feb; 50(1):347-359. PubMed ID: 34940787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. α4β7 expression guides B cells to front lines of defense in the gut.
    Shouval DS
    Mucosal Immunol; 2022 Feb; 15(2):192-194. PubMed ID: 34931001
    [No Abstract]   [Full Text] [Related]  

  • 38. Human influenza virus challenge identifies cellular correlates of protection for oral vaccination.
    McIlwain DR; Chen H; Rahil Z; Bidoki NH; Jiang S; Bjornson Z; Kolhatkar NS; Martinez CJ; Gaudillière B; Hedou J; Mukherjee N; Schürch CM; Trejo A; Affrime M; Bock B; Kim K; Liebowitz D; Aghaeepour N; Tucker SN; Nolan GP
    Cell Host Microbe; 2021 Dec; 29(12):1828-1837.e5. PubMed ID: 34784508
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advances in Human Norovirus Vaccine Research.
    Zhang M; Fu M; Hu Q
    Vaccines (Basel); 2021 Jul; 9(7):. PubMed ID: 34358148
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.